Fibrosis staging systems for HCV and NAFLD
| Stage | Ishak staging for HCV10 | METAVIR staging for HCV11 | NASH Clinical Research Network staging system for NAFLD12 |
|---|---|---|---|
| 0 | No fibrosis | No fibrosis | No fibrosis |
| 1 | Expansion of some portal areas with or without septa | Portal fibrosis without septa | Perisinusoidal or periportal fibrosis |
| 2 | Expansion of most portal areas with or without septa | Portal fibrosis with rare septa | Perisinusoidal and portal/periportal fibrosis |
| 3 | Expansion of most portal areas with occasional portal-portal bridging | Portal fibrosis with numerous septa | Bridging fibrosis |
| 4 | Expansion of portal areas with marked bridging (portal-portal, portal-central) | Cirrhosis | Cirrhosis |
| 5 | Marked bridging with occasional nodules (incomplete cirrhosis) | ||
| 6 | Cirrhosis |
HCV = hepatitis C virus; METAVIR = Meta-analysis of Histological Data in Viral Hepatitis; NAFLD = nonalcoholic fatty liver disease; NASH = nonalcoholic steatohepatitis